Status:
COMPLETED
Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
Brief Summary
To compare the proportion of rheumatoid arthritis (RA) patients prescribed opioids, benzodiazepines, and antidepressants before versus after starting each of the following biologics: abatacept, inflix...
Eligibility Criteria
Inclusion
- ICD 9 diagnosis RA 714.0
- Documented first biologic prescription ("index" prescription) for abatacept, infliximab, etanercept, or adalimumab
- Continuous therapy (gap between scripts no greater than 150% days supply) for minimum 6 months from index
- Prescription claims data available for 6 months before and 12 months after index biologic prescription
- Continuous eligibility for 6 months before and 12 months after index biologic prescription
Exclusion
- Prescription claims for another biologic during the observation period (including rituximab and anakinra)
- Prescriptions not continuous for at least 6 months
Key Trial Info
Start Date :
October 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
1810 Patients enrolled
Trial Details
Trial ID
NCT01137838
Start Date
October 1 2009
End Date
October 1 2010
Last Update
May 17 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.